NASDAQ:MRSN
Delisted

Mersana Therapeutics Stock Signals

etoro logo Buy MRSN
*Your capital is at risk
$29.08
+0 (+0%)
At Close: Apr 02, 2026

Latest Data & Signals Issued

Below are some of the latest signals issued for Mersana Therapeutics, Inc.

General

Signal Type Signal Value Data
Score 0.000 95 days ( -4.15 %
Last Price $29.08 0 %
Performance History
7 Days
$29.08 $29.08
0%
30 Days
$29.08 $29.08
0%
12 Mos
$0.340 $29.08
8,455.46%

7/18

Active Buy Signals

Specific Signals

Short Term
Net score: 25
Signal Type Signal Value Importance Data
High / Low N/A Very Low $29.08 - $29.08
Trend - 3 mos 0 % High Width: 0.00000000000015 %
Pred. range - 3 mos $29.08 - $29.08 Low 0 % - 0 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Apr 01, 2026 - 2 days
RSI Short Pivot Signal Sell Very Low Jan 20, 2026 - 52 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 74.41
Signal Type Signal Value Importance Data
Trend - 12 mos 41,813.88 % Very High Width: 66.26 %
Pred. range - 12 mos $10,013.17 - $16,647.94 High 34,333.17 % - 57,148.77 %
Short MA 12 mos Buy Very High Nov 12, 2025 - 97 days
Long MA 12 mos Buy Very High Aug 11, 2025 - 163 days
Short/Long MA 12 mos Buy Very High Aug 11, 2025 - 163 days
Pivot Long Sell Low Dec 24, 2025 - 68 days
RSI Long Pivot Signal Sell Low Jan 29, 2026 - 45 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT MERSANA THERAPEUTICS, INC.
Mersana Therapeutics
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ...
GOLDEN STAR
Ticker Change Signal Date
EAT
$140.46
13.43% Jun 05
TPR
$140.47
4.95% Jun 04
LITE
$905.00
1.83% Jun 01
RUN
$12.83
0.468% May 06
GLBE
$31.61
3.54% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE